INmune Bio (INMB) announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The closing of the Offering is expected to occur on or about June 30, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $19M, before deducting placement agent fees and other estimated offering expenses. The company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures. A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Unusually active option classes on open June 27th
- Inmune Bio to Present Phase 2 Trial Data
- INmune Bio put volume heavy and directionally bearish
- Inmune Bio’s Phase 2 Trial of XPro: Anticipated Catalyst for Stock Surge Amid Robust Design and High Short Interest
- Largest borrow rate increases among liquid names